February 2, 2015 | Israeli startup Nexense has raised $3 million at a valuation of $30 million for its snoring and sleep apnea treatment, which has already obtained CE marketing certification in Europe. The company says it has already sold 1,000 units of its product in Europe and Israel, and will use the new funding to develop the next generation of the product. Worn as a chest strap or wristwatch, the Nexense device monitors various physical parameters during sleep, and vibrates—without waking the sleeper—when it detects snoring or sleep apnea. The Ramat Gan-based company led by CEO Bary Molchadsky has already partnered with General Electric, which holds an 8% stake in the company.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments